Aurinia Pharmaceuticals Inc.

AUPH

$16.40

Updated: 24/09/2026, 09:59:03

Market Cap

$2.11B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for AUPH

Company Profile

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

USD

NASDAQ

CEO: Kevin C. Tang

Employees: 128

https://www.auriniapharma.com

Asset Summaries

Latest generated summaries for AUPH

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for AUPH.

Share price: $16.40
Market cap: $2.11B
Exchange: NASDAQ
Currency: USD
CEO: Kevin C. Tang
Employees: 128
IPO date: 03/09/2014
Beta: 1.408
Last dividend: $0.00
Day range: $16.27 – $16.91
52-week range: $10.34 – $19.25
1-day performance: -1.62%
1-year performance: 58.61%
Current drawdown (1Y): -14.81%
CIK: 0001600620
CUSIP: 05156V102
ISIN: CA05156V1022
Created: 07/12/2025, 02:13:09
Last update: 24/09/2026, 09:59:03

Track Aurinia Pharmaceuticals Inc. with an AI analyst

See which prediction-market events move AUPH, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to AUPH from your Railway `news_articles` table.

Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow

Seeking Alpha • STOCK • 04/06/2026, 10:33:06

Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript

Seeking Alpha • STOCK • 03/06/2026, 15:22:02

Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance

Seeking Alpha • STOCK • 27/03/2026, 17:15:55

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Capital Efficiency Analysis

Market Data • Market Data • 06/03/2026, 13:00:02

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript

Seeking Alpha • STOCK • 26/02/2026, 16:28:00

Aurinia Pharmaceuticals (AUPH) Tops Q4 Earnings and Revenue Estimates

Zacks Investment Research • STOCK • 26/02/2026, 10:16:00